CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 900 enrolled
Drug / intervention
Ticagrelor 90 MG Oral Tablet +1 moredrug
Likely dose
Ticagrelor 90 MG Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05553613
NCT05553613Phase 3Completed
CompareCT.gov

Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial

Kafrelsheikh University·interventional·Posted Sep 23, 2022·Updated May 14, 2024

In Brief

A Phase 3 clinical trial evaluating Ticagrelor 90 MG Oral Tablet and Clopidogrel tablet for Ischemic Stroke. Completed, enrolled 900 participants across 1 site.

Detailed Summary

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within the first 24 hours of first-ever ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS, mRS, duration of hospital stay, and possible adverse effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedSep 23, 2022
Enrollment StartOct 1, 2022
Primary CompletionOct 1, 2023
Study CompletionJan 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 3.8 years ago

Interventions

Ticagrelor 90 MG Oral Tabletdrug

Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Clopidogrel tabletdrug

efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.